McKesson (NYSE:MCK) Sets New 52-Week High Following Earnings Beat

McKesson Corporation (NYSE:MCK) hit a new 52-week high on Thursday following a stronger than expected earnings report. The stock traded as high as $964.94 and last traded at $958.92, with a volume of 586810 shares. The stock had previously closed at $822.00.

The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter last year, the company earned $8.03 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio is currently 10.21%.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat expectations: EPS topped consensus and revenue came in slightly above estimates, supporting the stronger outlook. McKesson earnings beat by $0.18, revenue topped estimates
• Positive Sentiment: Company raised full‑year adjusted EPS guidance to $38.80–$39.20 (slightly above consensus), signaling confidence in oncology and biopharma services growth. McKesson raises full-year EPS guidance to $38.80–$39.20
• Positive Sentiment: Street coverage highlights stronger profit outlook driven by specialty drug and oncology distribution, underpinning the guidance upgrade. McKesson boosts 2026 profit forecast amid specialty drug growth
• Neutral Sentiment: Analyst update: Mizuho nudged its price target from $880 to $885 but kept a “neutral” rating — a modest signal of upside without a conviction upgrade. Mizuho raises price target on McKesson to $885
• Neutral Sentiment: Investor materials and the earnings call transcript/slides are available for details on segment performance and management commentary (useful for modeling FY26 cadence). McKesson Q3 2026 Earnings Call Transcript
• Negative Sentiment: Cash flow weakness flagged: reports note materially weaker operating cash flow this quarter and higher total liabilities, which could pressure free cash flow and leverage metrics despite profit growth. EPS Beats, Profit Growth but Weak Operating Cash Flow
• Negative Sentiment: Corporate action: McKesson has fully exited its European market, a strategic shift that may reduce geographic diversification and near‑term revenue base in that region. McKesson fully exits European market

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MCK. Evercore ISI reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of McKesson in a research report on Thursday, November 6th. TD Cowen restated a “buy” rating on shares of McKesson in a research note on Thursday. Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Jefferies Financial Group upped their price objective on shares of McKesson from $820.00 to $900.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Finally, Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average target price of $908.36.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $861.63, for a total transaction of $283,476.27. Following the completion of the sale, the chief accounting officer owned 328 shares of the company’s stock, valued at approximately $282,614.64. This represents a 50.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction on Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.08% of the company’s stock.

Hedge Funds Weigh In On McKesson

Several hedge funds and other institutional investors have recently modified their holdings of MCK. GGM Financials LLC purchased a new stake in McKesson in the third quarter worth $25,000. Solstein Capital LLC boosted its holdings in shares of McKesson by 171.4% during the 2nd quarter. Solstein Capital LLC now owns 38 shares of the company’s stock valued at $28,000 after buying an additional 24 shares in the last quarter. State of Wyoming purchased a new stake in shares of McKesson in the 2nd quarter worth about $29,000. GFG Capital LLC bought a new position in shares of McKesson in the 2nd quarter worth about $30,000. Finally, Hopwood Financial Services Inc. purchased a new position in McKesson during the 3rd quarter valued at about $31,000. 85.07% of the stock is owned by institutional investors.

McKesson Stock Performance

The business’s 50-day moving average is $825.54 and its 200-day moving average is $776.66. The company has a market capitalization of $118.14 billion, a PE ratio of 29.94, a PEG ratio of 1.40 and a beta of 0.40.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.